Andere talen KORU Medical Systems, Inc.

Aandelen

KRMD

US7599101026

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,25 ^USD	+3,69%		+2,27%	-8,35%

13/03	Transcript : KORU Medical Systems, Inc., Q4 2023 Earnings Call, Mar 13, 2024
13/03	KORU Medical Systems, Inc. rapporteert resultaten voor het vierde kwartaal dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Posts Q1 Revenue $8.2M, vs. Street Est of $7.5M	01/05
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth	01/05
KORU Medical Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024	17/04
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review	11/04
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference	18/03
KORU Medical Systems, Inc. Enters into Loan and Security Agreement with HSBC Ventures USA Inc	13/03
KORU Medical Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03
KORU Medical Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Reports Q4 Revenue $7.2M, vs. Street Est of $6.9M	13/03
KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance	13/03
KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year 2024	13/03
KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic	11/03
KORU Medical Systems, Inc. Announces A Feasibility Study to Enter Ambulatory Infusion Settings with A Commercialized Biologic	11/03
KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin	06/03
KORU Medical Systems, Inc. Signs Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for Novel Subcutaneous Immunoglobulin	06/03
KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024	21/02
KORU Medical : Investor Day 2023 Presentation	05/12
KORU Medical Systems to Participate in Piper Sandler's 35th Annual Healthcare Conference	30/11
KORU Medical Systems to Participate in Piper Sandler’s 35th Annual Healthcare Conference	29/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen KORU Medical Systems, Inc.

Aandelen

KRMD

US7599101026

Andere talen

Filters